Profound Medical Unveils Q2 2024 Financials
Company Announcements

Profound Medical Unveils Q2 2024 Financials

Story Highlights

Profound Medical (TSE:PRN) has released an update.

Profound Medical Corp. is set to announce its Q2 2024 financial results on August 8, followed by a conference call to discuss the company’s business developments. Investors can tune into the live call via the company’s website or through a provided registration link. Profound is known for its innovative, incision-free therapies for tissue ablation, including TULSA-PRO for prostate issues and Sonalleve for uterine fibroids and bone metastases pain relief.

For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyProfound Medical reports Q3 EPS (38c), consensus (30c)
TipRanks Auto-Generated NewsdeskProfound Medical Sees Strong Growth with TULSA-PRO®
TipRanks Canadian Auto-Generated NewsdeskProfound Medical’s TULSA Gains CMS Reimbursement Boost
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App